Inpatient Mortality With Renal Impairment in Patients With Multiple Myeloma

This article was originally published by Cancer Therapy Advisor

Receipt of dialysis may be a risk factor for inpatient mortality in patients with multiple myeloma (MM) being treated with high-dose melphalan and autologous stem cell transplantation (HDM-ASCT), according to study results published in the European Journal of Haematology.

To evaluate inpatient mortality trends, investigators conducted a retrospective analysis of hospital admissions for patients with MM and end-stage renal disease or chronic kidney disease who were treated with HDM-ASCT. End-stage renal disease required the use of dialysis, and chronic kidney disease was defined as having a creatinine clearance of below 60 mL/mm/1.73 m2 but without the need for dialysis.

Patient records used for analysis were from 2002 to 2014, and were identified through the National Inpatient Sample database. While the database accounted for approximately 20% of hospital discharges in the United States, weighted estimates allowed for extrapolation to hospitalizations across the nation.

To continue reading on …